Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » Sequencing » Advaxis Taps Personalis for Biomarker Discovery in Lung Cancer Immunotherapy Program

Advaxis Taps Personalis for Biomarker Discovery in Lung Cancer Immunotherapy Program

Feb 11, 2020
|
staff reporter

NEW YORK – Immunotherapy developer Advaxis and sequencing firm Personalis said today that they have entered an extended collaboration agreement, under which they are using Personalis' ImmunoID NeXT Platform for biomarker discovery in Advaxis' ongoing Phase I/II program advancing the investigational ADXS-503 alone and in combination with pembrolizumab for patients with non-small cell lung cancer.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Jul
16
Featured Webinar

Exploring Tumor Tissue Architecture and Immune Response with Digital Spatial Profiling

Sponsored by
NanoString

Join this webinar to learn how spatial resolution of gene expression in tumor tissue reveals new insights in biomarker discovery and therapeutic response. 

Jul
23
Featured Webinar

Clinical Utility of Liquid Biopsy for the Detection of T790M to Guide Lung Cancer Treatment Strategy

Sponsored by
Roche

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.

Jul
29
Featured Webinar

Life Science Marketing Workshop: Creating a Go-To-Market Strategy in a Rapidly Evolving Sector

Sponsored by
Illumina

“If we build it, they will come” is a familiar refrain that echoes in life science entrepreneurial circles. Too frequently startups believe that if a technology is built it will sell.

Aug
25
Featured Webinar

Liquid Biopsy-based Molecular Risk Stratification of ALK-mutated Lung Cancer Patients

Sponsored by
Roche

Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.

What's Popular?

In Cancer

  1. AnchorDx Demonstrates Liquid Biopsy DNA Methylation Test for Early Cancer Detection

    Premium

  2. Foundation Medicine Shifts Focus to Early Cancer Detection With Lexent Bio Acquisition

    Premium

  3. Polygenic Risk Score Modifies Breast Cancer Risk in Pathogenic Variant Carriers

  4. Oncotype DX Predicts Outcomes in Men With Unfavorable Intermediate-Risk Prostate Cancer, Study Finds

    Premium

  5. OncoCyte Downgraded to Neutral by Piper Sandler on Unsuccessful Results for Lung Cancer Test

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.